Apyx Medical Corporation

NASDAQ:APYX

Medical - Devices

Healthcare
$2.49 -1.90%

-$0.08 today

Market cap
$104.89M
Beta
1.39
P/E (TTM)
-19.0
EPS (TTM)
-$0.22
52W Low $1.59High $5.08

Volume 0.19M

Average 0.18M

APYX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Apyx Medical CorporationNASDAQ: APYX

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $765K fell 4.9% year over year, ahead of the -25.7% change in trailing-twelve-month research & development. Sequentially, it fell 19.0% from the prior quarter. Over 3 fiscal years it compounded at -9.5% a year.

Context

  • Research & development amounted to 6.4% of revenue in FY2025, down 4.2 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -4.9% holds above the trailing-twelve-month pace of -25.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$765K-19.0% QoQ
Last fiscal yearDec 2025
$3.37M-33.6% YoY
LTMMar 2026
$3.33M-25.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-4.9%——
1 year-33.6%——
3-year CAGR-9.5%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
3.37M USD
Year-over-year change
-33.6%
4-year CAGR
-6.0%

Research & Development vs competitors

How APYX compares with its peers on the latest reported figures

  • APYX's LTM Mar 2026 research & development of $3.33M is the 6th highest of the 8 companies compared; the peer median is $12.87M.
  • Its year-over-year change of -25.7% is the lowest of 8, against a peer median of -7.8%.
  • Research & development amounts to 6.0% of revenue for APYX, versus a peer median of 33.3%.
APYX Competitors Peer median
Research & Development for APYX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RCELAVITA Medical, Inc.LTM Mar 2026$20.18M -5.9%+14.6%27.9%
VANIVivani Medical, Inc.LTM Mar 2026$18.17M +11.9%+8.6%—
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$13.34M -7.2%+1.9%38.8%
SERASera Prognostics, Inc.LTM Mar 2026$12.87M -10.5%-2.6%22573.7%
LUCDLucid Diagnostics Inc.LTM Mar 2026$5.46M -7.8%+691.2%106.3%
APYXApyx Medical CorporationLTM Mar 2026$3.33M -25.7%-9.5%6.0%
PDEXPro-Dex, Inc.LTM Mar 2026$3.23M -9.4%+6.9%4.3%
XTNTXtant Medical Holdings, Inc.LTM Mar 2026$2.09M -9.0%+31.9%1.7%
Peer median (excluding APYX) $12.87M-7.8%+8.6%33.3%

Competitors are the stored peer set for APYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue48.52M44.51M52.35M48.1M52.84M
Cost of Revenue14.92M15.38M18.59M18.74M33.81M
Gross Profit33.6M29.13M33.76M29.36M19.03M
Gross Margin69.3%65.4%64.5%61.0%36.0%
Research & Development4.32M4.54M4.84M5.08M3.37M
Selling, General & Admin43.73M48.15M48.87M43.13M36.12M
Operating Expenses48.05M52.69M51.02M48.21M25.48M
Depreciation & Amortization903K890K692K599K655K
EBITDA(13.91M)(22.01M)(18.11M)(16.8M)(4.59M)
EBITDA Margin-28.7%-49.4%-34.6%-34.9%-8.7%
Operating Income(14.45M)(23.56M)(17.26M)(18.85M)(6.45M)
Operating Margin-29.8%-52.9%-33.0%-39.2%-12.2%
Interest Income11K157K921K1.61M1.11M
Interest Expense10K15K2.48M5.91M5.59M
Other Income / Expenses(372K)651K(4.02M)(4.46M)(4.39M)
Income Before Tax(14.82M)(22.91M)(21.28M)(23.31M)(10.84M)
Pre-Tax Margin-30.5%-51.5%-40.7%-48.5%-20.5%
Income Tax Expense380K367K(2.43M)252K270K
Net Income(15.17M)(23.18M)(18.71M)(23.46M)(11.21M)
Net Margin-31.3%-52.1%-35.7%-48.8%-21.2%
EPS (Basic)(0.44)(0.67)(0.54)(0.66)(0.27)
EPS (Diluted)(0.44)(0.67)(0.54)(0.66)(0.27)
Weighted Avg Shares34.33M34.52M34.62M35.54M42.16M
Weighted Avg Shares (Diluted)34.33M34.52M34.62M35.54M42.16M

Apyx Medical Corporation

NASDAQ:APYX

Intrinsic Alpha fair value

Locked

Current Price

$2.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.